Current status of early gastric cancer screening research

References

1. 1.↵
   2. Sung H,
   3. Ferlay J,
   4. Siegel RL,
   5. Laversanne M,
   6. Soerjomataram I,
   7. Jemal A, et al.

   Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209–49.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. Wang Z,
   3. Han W,
   4. Xue F,
   5. Zhao Y,
   6. Wu P,
   7. Chen Y, et al.

   Nationwide gastric cancer prevention in China, 2021-2035: a decision analysis on effect, affordability and cost-effectiveness optimisation. Gut. 2022; 71: 2391–400.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   2. Jun JK,
   3. Choi KS,
   4. Lee H-Y,
   5. Suh M,
   6. Park B,
   7. Song SH, et al.

   Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology. 2017; 152: 1319–28.e7.

   OpenUrlPubMed
4. 4.↵
   2. Hamashima C,
   3. Goto R.

   Potential capacity of endoscopic screening for gastric cancer in Japan. Cancer Sci. 2017; 108: 101–7.

   OpenUrl
5. 5.↵
   2. Choi KS,
   3. Kwak M-S,
   4. Lee H-Y,
   5. Jun JK,
   6. Hahm M-I,
   7. Park E-C.

   Screening for gastric cancer in Korea: population-based preferences for endoscopy versus upper gastrointestinal series. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1390–8.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   2. Sin M-K,
   3. Kim I-H.

   Facilitators of and barriers to gastric cancer screening among Korean Americans. Cancer Nurs. 2017; 40: E59–65.

   OpenUrlPubMed
7. 7.↵
   2. Machlowska J,
   3. Baj J,
   4. Sitarz M,
   5. Maciejewski R,
   6. Sitarz R.

   Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020; 21: 4012.

   OpenUrlCrossRef
8. 8.↵
   2. Usui Y,
   3. Taniyama Y,
   4. Endo M,
   5. Koyanagi YN,
   6. Kasugai Y,
   7. Oze I, et al.

   Helicobacter pylori, homologous-recombination genes, and gastric cancer. N Engl J Med. 2023; 388: 1181–90.

   OpenUrl
9. 9.↵
   2. Sun L,
   3. Tu H,
   4. Liu J,
   5. Gong Y,
   6. Xu Q,
   7. Jing J, et al.

   A comprehensive evaluation of fasting serum gastrin-17 as a predictor of diseased stomach in Chinese population. Scand J Gastroenterol. 2014; 49: 1164–72.

   OpenUrlCrossRefPubMed
10. 10.↵
    2. Miki K.

    Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006; 9: 245–53.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Yamaguchi Y,
    3. Nagata Y,
    4. Hiratsuka R,
    5. Kawase Y,
    6. Tominaga T,
    7. Takeuchi S, et al.

    Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels--the ABC method. Digestion. 2016; 93: 13–8.

    OpenUrl
12. 12.↵
    2. Watabe H,
    3. Mitsushima T,
    4. Yamaji Y,
    5. Okamoto M,
    6. Wada R,
    7. Kokubo T, et al.

    Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005; 54: 764–8.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    2. Saito S,
    3. Azumi M,
    4. Muneoka Y,
    5. Nishino K,
    6. Ishikawa T,
    7. Sato Y, et al.

    Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan. Eur J Health Econ. 2018; 19: 545–55.

    OpenUrl
14. 14.↵
    2. Cai Q,
    3. Zhu C,
    4. Yuan Y,
    5. Feng Q,
    6. Feng Y,
    7. Hao Y, et al.

    Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study. Gut. 2019; 68: 1576–87.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    2. Maron SB,
    3. Chase LM,
    4. Lomnicki S,
    5. Kochanny S,
    6. Moore KL,
    7. Joshi SS, et al.

    Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin Cancer Res. 2019; 25: 7098–112.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    2. Necula L,
    3. Matei L,
    4. Dragu D,
    5. Neagu AI,
    6. Mambet C,
    7. Nedeianu S, et al.

    Recent advances in gastric cancer early diagnosis. World J Gastroenterol. 2019; 25: 2029–44.

    OpenUrlCrossRefPubMed
17. 17.↵
    2. So JBY,
    3. Kapoor R,
    4. Zhu F,
    5. Koh C,
    6. Zhou L,
    7. Zou R, et al.

    Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut. 2021; 70: 829–37.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    2. Guo X,
    3. Peng Y,
    4. Song Q,
    5. Wei J,
    6. Wang X,
    7. Ru Y, et al.

    A liquid biopsy signature for the early detection of gastric cancer in patients. Gastroenterology. 2023; 165: 402–13.e13.

    OpenUrl
19. 19.↵
    2. Xu Z,
    3. Huang Y,
    4. Hu C,
    5. Du L,
    6. Du YA,
    7. Zhang Y, et al.

    Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: a large-scale, multicentre study. Gut. 2023; 72: 2051–67.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    2. Wu L,
    3. Xu M,
    4. Jiang X,
    5. He X,
    6. Zhang H,
    7. Ai Y, et al.

    Real-time artificial intelligence for detecting focal lesions and diagnosing neoplasms of the stomach by white-light endoscopy (with videos). Gastrointest Endosc. 2022; 95: 269–80.e6.

    OpenUrl
21. 21.↵
    2. Yuan L,
    3. Yang L,
    4. Zhang S,
    5. Xu Z,
    6. Qin J,
    7. Shi Y, et al.

    Development of a tongue image-based machine learning tool for the diagnosis of gastric cancer: a prospective multicentre clinical cohort study. EClinicalMedicine. 2023; 57: 101834.